NCT03092934View on ClinicalTrials.gov

A Study of AK-01 (LY3295668) in Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 29, 2017

Primary Completion Date

April 20, 2020

Study Completion Date

April 20, 2020

Conditions
NeoplasmsNeoplasm MetastasisTriple Negative Breast NeoplasmsHead and Neck NeoplasmsBreast NeoplasmsSolid Tumor, AdultSmall Cell Lung Carcinoma
Interventions
DRUG

LY3295668

Oral capsules

Trial Locations (3)

T6G 1Z2

Cross Cancer Institute, Edmonton

H3T 1E2

Jewish General Hospital, Montreal

H4A 3J1

McGill University, Montreal

Sponsors

Collaborators (1)

AurKa Pharma Inc.
All Listed Sponsors
collaborator

AurKa Pharma Inc.

OTHER

lead

Eli Lilly and Company

INDUSTRY